VSV-EBOVAC Consortium reports that a dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa
The VSV-EBOVAC Consortium has collaborated in the study “A dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa” published in Science Translational Medicine journal.
The rVSV-ZEBOV vaccine, based on the replication-competent recombinant vesicular stomatitis virus (VSV) expressing a Zaire ebolavirus (EBOV) glycoprotein, is currently the only Ebola vaccine with demonstrated efficacy in Phase III clinical trials. This vaccine was used in Guinea during the recent outbreak and has now been shown to be incredibly effective in preventing infection.
The study published today in Science Translational Medicine examined longitudinal plasma samples from vaccine recipients in Europe and Africa to identify a signature of the immune response and adverse events. The signature of monocyte-derived cytokines held true in both cohorts, suggesting that it could also be applied to other vaccine trials to determine immunogenicity and reactogenicity.
Full text link.
A Research Topic "Advanced Immunization Technologies for Next Generation Vaccines” is to be published in Frontiers in Immunology, Section Vaccines and Molecular Therapeutics.
Scientists are invited to submit original articles by following this link
After vaccine success, Ebola work must continue
Professor Claire-Anne Siegrist from the University of Geneva in Switzerland, the principal investigator of the Geneva clinical trial, and Donata Medaglini the coordinator of the VSV-EBOVAC project, discuss the Ebola trail for the "EU Research and Innovation Magazine_ HORIZON".
The efficacy and effectiveness of the rVSV-ZEBOV vaccine
The efficacy and effectiveness of rVSV-vectored vaccine in preventing Ebola virus disease was demostrated in a Guinea ring vaccination, open-label, cluster-randomised trail.
The resultsadd weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters.Read more here.
The European Parliament holds an event on "Vaccine Research and Development in Europe" highlighting the ADITEC project success story
The Science and Technology Options Assessment (STOA) of the European Parliament, organizes an event "Working Breakfast on Vaccine Research and Development in Europe". This is a great opportunity to discuss about vaccines research & development activities in Europe, future developments and the role of the ADITEC project in this field. Politicians, Representatives from the European Commission and from other organizations, and leading experts in the field of vaccines R&D will participate to the event. The event will take place on November 8, 2016 between 8 am and 9 am.
The participation to the Parliament event is only possible by registration at http://www.europarl.europa.eu/stoa/cms/, with a limited number of spaces available.
Roadmap to bolster vaccine innovation launched in european parliament
The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) - financed under the EU 7th Framework Programme (FP7) – launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years. Read more
Press releases on:
Ebola vaccineR&D: Filling the knowledge gaps
With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine and ensures that such information is shared among stakeholders.
Downolad the full paper
Efficacy and effectiveness of Ebola vaccine
Researchers have announced that the rVSV-ZEBOV vaccine has shown 100 % effectiveness in a Phase III large-scale trial of over 7000 people in Guinea.
These results suggest that the efficacy of a single injection of rVSV-ZEBOV to prevent Ebola virus disease might be high, that protection can be established quickly, and that the vaccine might be effective at the population level when delivered by ring vaccination.
BVAPS 2016: ‘Biomarkers of Vaccine/Adjuvant Potency and Safety' conference, 6 - 8 April 2016, Porto, Portugal
This new international conference will offer a forum for an update on recent developments and future challenges relating to ‘Biomarkers of Vaccine/Adjuvant Potency and Safety'.
The inaugural BVAPS 2016 meeting will draw on the latest life science research findings to profile how individuals respond to the different components of vaccines at the cellular, genetic and molecular level. Identification and characterization of new biomarkers useful to predict immunogenicity, efficacy and reactogenicity of vaccines given systemically or mucosally will be a main focus of the conference along with discussions on new ways to identify and classify these biomarkers. The impact of genetic background and age on the vaccine efficacy and safety will also be covered by the meeting. It is envisaged that identification of novel ways to better understand the mechanisms of actions of vaccines and adjuvants at all stages of development will enable the acceleration of the development and introduction of a new generation of safer and more effective vaccines. Recent development in cutting-edge technologies such as omics and systems vaccinology alongside state-of-the-art immunological methods that enable in-depth analysis of vaccine immunogenicity, efficacy and safety will also be a focus of the BVAPS 2016 meeting.
Read more on the meeting website pages